Kumquat Biosciences Inc.

This early-phase study tests a new oral drug, KQB168, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to immunotherapy. The main goals are to find a safe dose and see if the drug can shrink tumors. About 84 participants will take the…

This early-phase study tests a new drug called KQB365 in adults with advanced solid tumors that have KRAS G12S or G12C mutations and no standard treatment options. The main goals are to find a safe dose and see if KQB365 alone or combined with other drugs (cetuximab or KQB198) ca…

This study tests whether adding an experimental drug, KQB198, to the standard cancer drug imatinib is safe and works better for people with advanced gastrointestinal stromal tumor (GIST). About 46 adults with a specific gene mutation (KIT or PDGFRA) will receive the combination a…

This early-stage trial tests a new drug called KQB548 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have a specific genetic change called KRAS G12D. The main goals are to find a safe dose and see if the drug can shrink tumors. About 78 pa…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have certain genetic changes. The study aims to find safe doses of KQB198 alone or with other cancer drugs, and to see if it can shrink tumors. About 100 participants will take the dru…